U.S. flag

An official website of the United States government

NM_000551.4(VHL):c.263_265dup (p.Trp88_Leu89insArg) AND Hereditary cancer-predisposing syndrome

Germline classification:
Likely pathogenic (1 submission)
Last evaluated:
Jun 1, 2018
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000492430.4

Allele description [Variation Report for NM_000551.4(VHL):c.263_265dup (p.Trp88_Leu89insArg)]

NM_000551.4(VHL):c.263_265dup (p.Trp88_Leu89insArg)

Gene:
VHL:von Hippel-Lindau tumor suppressor [Gene - OMIM - HGNC]
Variant type:
Duplication
Cytogenetic location:
3p25.3
Genomic location:
Preferred name:
NM_000551.4(VHL):c.263_265dup (p.Trp88_Leu89insArg)
HGVS:
  • NC_000003.12:g.10142110_10142112dup
  • NG_008212.3:g.5476_5478dup
  • NM_000551.4:c.263_265dupMANE SELECT
  • NM_001354723.2:c.263_265dup
  • NM_198156.3:c.263_265dup
  • NP_000542.1:p.Trp88_Leu89insArg
  • NP_001341652.1:p.Trp88_Leu89insArg
  • NP_937799.1:p.Trp88_Leu89insArg
  • LRG_322:g.5476_5478dup
  • NC_000003.11:g.10183794_10183796dup
  • NM_000551.3:c.263_265dupGGC
Links:
dbSNP: rs1131690960
NCBI 1000 Genomes Browser:
rs1131690960
Molecular consequence:
  • NM_000551.4:c.263_265dup - inframe_insertion - [Sequence Ontology: SO:0001821]
  • NM_001354723.2:c.263_265dup - inframe_insertion - [Sequence Ontology: SO:0001821]
  • NM_198156.3:c.263_265dup - inframe_insertion - [Sequence Ontology: SO:0001821]

Condition(s)

Name:
Hereditary cancer-predisposing syndrome
Synonyms:
Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000580983Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)
Likely pathogenic
(Jun 1, 2018)
germlineclinical testing

PubMed (2)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling.

Min JH, Yang H, Ivan M, Gertler F, Kaelin WG Jr, Pavletich NP.

Science. 2002 Jun 7;296(5574):1886-9. Epub 2002 May 9.

PubMed [citation]
PMID:
12004076

Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1α protein-protein interface.

Van Molle I, Thomann A, Buckley DL, So EC, Lang S, Crews CM, Ciulli A.

Chem Biol. 2012 Oct 26;19(10):1300-12. doi: 10.1016/j.chembiol.2012.08.015.

PubMed [citation]
PMID:
23102223
PMCID:
PMC3551621

Details of each submission

From Ambry Genetics, SCV000580983.6

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (2)

Description

The c.263_265dupGGC variant (also known as p.W88_L89insR), located in coding exon 1 of the VHL gene, results from an in-frame duplication of GGC at nucleotide positions 263 to 265, and results in the insertion of an extra arginine residue between codons 88 and 89. This alteration has been identified in unrelated individuals meeting diagnostic criteria for Von Hippel-Lindau (VHL) (Ambry internal data). Further, multiple similar non-truncating alterations in this region (p.W88R, p.W88L, p.W88C, p.L89P) have been reported in individuals satisfying established diagnostic criteria for VHL (Chen F, Hum. Mutat. 1995 ; 5(1):66-75, Kondo, et al. Hum. Mol. Genet. 1995 Dec; 4(12):2233-7, Gläsker S, J. Neurol. Neurosurg. Psychiatr. 1999 Dec; 67(6):758-62, Rocha JC, J. Med. Genet. 2003 Mar; 40(3):e31; Ong KR et al. Hum Mutat. 2007;28(2):143-149). In addition, based on internal structural assessment, this alteration results in local structural perturbation of the VHL protein fold, near the HIF1α-peptide-binding site (Min JH et al. Science, 2002 Jun;296:1886-9; Van Molle I et al. Chem. Biol., 2012 Oct;19:1300-12). The duplicated nucleotide region is highly conserved in available vertebrate species. Based on the majority of available evidence to date, this variant is likely to be pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: May 1, 2024